Melafenoxate, 2-(1-adamantylamino)ethyl 2-(4-chlorophenoxy)acetate and derivatives thereof for treating circadian rhythm sleep disorders with neurodegenerative diseases such as Alzheimer's disease
AssigneeNLS Pharmaceutics AG
InventorEric KONOFAL
Life of this patent
Estimating the term…
Abstract
The invention concerns a compound of formula (I) R1=H or acyl group, preferably R1=H; R2=halogen atom selected in the group consisting of: F, Cl, Br, I, preferably R2=Cl or a pharmaceutically acceptable isomer, salt and/or solvate thereof, for use in preventing and/or treating circadian rhythm sleep disorders and/or circadian rhythm sleep neurological diseases and/or any medical condition associated due to sleep deprivation.
Claims20
1-15. (canceled)
A method of prevention and/or treatment of circadian rhythm sleep disorders and/or circadian rhythm sleep neurological diseases and/or any medical condition associated due to sleep deprivation and/or circadian rhythm disruption and/or central disorders of hypersomnolence, comprising the administration of a compound of formula (I)
- with R1=H or an acyl group, and
- R2=a halogen atom selected in the group consisting of F, Cl, Br and I, or a pharmaceutically acceptable isomer, salt and/or solvate thereof, to a patient in need thereof.
Dependencies are inferred from the claim text.